YS Biopharma Co., Ltd. - LSB EV/EBITDA Multiple

Graphic logo of YS Biopharma Co., Ltd. (LSB)

This EV/EBITDA chart for LakeShore Biopharma Co. (LSB) helps assess the expansion of the Chinese leader in anti-rabies vaccines, which is penetrating the infectious disease protection market via mRNA technologies. The current metric stands at . Despite a liquidity shortage driven by costly research, the business relies on patents that ensure global distribution of drugs with low unit economics.

LakeShore Biopharma Co., Ltd. - LSB Company Value to EBITDA (period 07/04/2022 - 11/11/2026)

Analytical breakdowns for ysbiopharm.com (LSB)

- market price and analyst price targets:
Price Chart YS Biopharma|LSB - Broker Consensus Forecast
- issuer market value details:
Market Capitalization LSB|LSB - Full Business Value
- issuer book value statistics:
Book Value per Share LakeShore Biopharma|LSB - Total Stockholders' Equity|Market Capitalization to Book Value Ratio ysbiopharm.com|LSB - Cumulative Company Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio LakeShore Biopharma Co.|LSB - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital LakeShore Biopharma|LSB - Company Total Debt Obligations|Debt to Book Capitalization Ratio LSB|LSB - Long-Term Debt|Company Short-Term Debt LakeShore Biopharma|Quick Liquidity ysbiopharm.com
- financial results and valuation multiples details:
LSB - Net Financial Result|Expected Profit LakeShore Biopharma Co.|LSB - Price to Earnings Ratio|Forward P/E Multiple LakeShore Biopharma Co.|LSB - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LSB|LSB - Operating profit EBITDA|Net earnings per share (EPS TTM) LakeShore Biopharma|LSB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months ysbiopharm.com|LSB - Expected net earnings per share growth this year|Earnings growth forecast for next year LakeShore Biopharma Co.
Comprehensive company analysis:LSB (YS Biopharma)
Manufactured products of ysbiopharm.com

Professional managers utilize fundamental filters to assess the value of assets with high debt loads and significant tax liabilities. This metric compares the total enterprise value to operating profit, which is critical for LakeShore Biopharma Co. (LSB) given its capital-intensive bio-plants and government tenders; analyzing the company's current EV/EBITDA ratio allows for the identification of a discounted entry point, avoiding value traps.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Summit Therapeutics Inc SMMT|MRNA: Enterprise Value to Operating Income Before Depreciation|Vaxcyte, Inc. - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio TARS|CRMD: EV/EBITDA Multiple|Company Value to EBITDA Seres Therapeutics Inc. (MCRB)|SPRO (Spero) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Scynexis (SCYX)|Enterprise Value to EBITDA Ratio ANTX (AN2 Therapeutics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio PYPD|EV/EBITDA Multiple ITRM (Iterum Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio BiomX Inc (PHGE)|SNGX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA 60 Degrees Pharmaceuticals|Oragenics, Inc. (OGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OPGN